NeuroDiversity Consulting LLC
  • Home
    • Our Mission
    • Events
    • Contact Us
  • Autism Attitude
  • Community
    • Stronger Together
    • Race and Disability

ASD and the Cannabinoids

8/4/2014

0 Comments

 
This post is part of the series Examining the Use of Medical Marijuana for ASD Treatment.

Given the apparent disregulation of activity in and between various neuronal networks in the autistic brain it is easy to see the appeal of marijuana to artificially stimulate the endocannabinoid system. But it is unclear what happens when you try to artificially stimulate the brain’s natural breaking system. One must proceed with the same caution one would employ when evaluating the use of other pharmaceuticals commonly prescribed to treat some of the symptoms and behaviors common in ASD.

It is important for parents to be aware of marijuana intoxication syndrome. In typically functioning individuals symptoms can range from giddiness to depression, introspection, and a sense of time moving slowly. How an autistic individual may react will depend on the baseline function of their endocannabinoid system.

Endocannabinoid system functionality is complex. We don’t have a reliable way to measure it. In fact we are still learning how this system works. Since we as yet have no way to measure endocannabinoid functionality parents will have to keep meticulous notes on their child’s behavior before, during, and after administering the preferred Cannabis product. A few of the many areas to monitor are:

·         motor function (walking, running, hand-eye coordination)

·         stability of mood

·         appetite

·         responses to stressful or new environments

·         blood pressure

·         sleep-wake cycle

Keep in mind that you may see improvement or deterioration in these and other areas with the administration of cannabinoids. Also keep in mind that your evaluation of functionality in these areas will be somewhat subjective. Consider having one or more independent observers, who are unaware of when or if your child has been administered a preparation of cannabinoids, monitor these areas as well.

Further consideration should be given to the following factors before making a decision about using medical ma. There has been little scientific research into the use of Cannabis products for the treatment of ASD. It also remains unclear what, if any, side effects may manifest in children with ASD given Cannabis products for any length of time. While the manufacturers of drugs for medical use are regulated and required by law to provide information about composition and efficacy of their products the manufacturers of Cannabis products are not. Furthermore, while drug companies are required to track and disclose any possible side effects of the products no such requirements currently exist for the manufacturers of Cannabis products. It remains unclear if manufacturers of Cannabis products will be subject to regulation similar to that of other drug companies. Currently New York State does not have a legal manufacturing base for Cannabis products. It remains to be seen whether or not one will be established.


Next up, NYS Medical Marijuana Law Summary.
0 Comments



Leave a Reply.

    Categories

    All
    504 Plan
    ABLE 2.0
    ABLE Act 2014
    ACE
    Aspergers
    Autism
    Autism Acceptance
    Autism Advisory Board
    Autism Awareness
    Autism Spectrum Disorder
    Autistic Adults
    Autistic Children
    Behavior Intervention Plan
    BIP
    Church
    Cure
    Diagnosis
    Diet
    Disability
    Discipline
    Diy
    Dsm
    Education
    Education Law
    Encouragement
    Epidemic
    Estate Planning
    Faith
    FBA
    Functional Behavioral Assessment
    Homeschooling
    IDEA
    IEP
    Incidence
    Inclusion
    Laws
    Long Term Care
    Mental Health
    Neurodevelopmental Disorder
    Neurodiversity
    New York
    Nha
    Nurtured Heart Approach
    Parenting
    PDD NOS
    PDD-NOS
    Person/people First Language
    Policy
    Prevalence
    Prevention
    Relativism
    Research
    Resilience
    School
    Science
    Sex
    Social Isolation
    Special Education Law
    Special Needs
    Suspension
    Trauma
    Treatment

    Archives

    December 2021
    November 2021
    October 2021
    March 2021
    February 2021
    December 2020
    May 2020
    September 2019
    August 2019
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    August 2017
    July 2017
    May 2017
    April 2017
    December 2016
    May 2016
    April 2016
    January 2016
    August 2015
    June 2015
    February 2015
    August 2014
    July 2014
    June 2014
    May 2014
    September 2013
    July 2013
    June 2013
    November 2012
    July 2012
    March 2012
    February 2012
    January 2012
    November 2011
    October 2011
    August 2011

      RSS Feed

    NeuroDiversity Consulting LLC
    info@neurodiversityconsulting.org

    (315) 760-4358
     Privacy Policy
    Business Credit
    Business Credit by Nav
    Photo used under Creative Commons from Hayzphotos
    • Home
      • Our Mission
      • Events
      • Contact Us
    • Autism Attitude
    • Community
      • Stronger Together
      • Race and Disability